Adaptimmune is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products for people with cancer. The Company\'s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors.
Our company culture is rooted in trust, inclusion, our capacity to collaborate, and our commitment to being honest and brave in our desire to successfully transform the lives of people with cancer.
Adaptimmune\xe2\x80\x99s Off-the-Shelf T cell project is focused on the development of an iPSC derived T-cell product. The project team is growing rapidly to enable delivery of a ground-breaking new therapy and ensure the company\xe2\x80\x99s position as a leader in the allogeneic cell therapy field. We seek a talented and motivated individual with expertise in cell and molecular biology to join the expanding gene editing team.
Reporting to the Group Leader, individual will be responsible for performing transgene knock-in /gene inactivation, isolation and genotyping of single cell clones, molecular characterisation, next-generation sequencing (NGS), and construct cloning. The postholder will also perform cell culture of induced pluripotent stem cells (iPSC) to support Adaptimmune\xe2\x80\x99s gene editing pipeline.
Key Responsibilities
MNCJobs.co.uk will not be responsible for any payment made to a third-party. All Terms of Use are applicable.